Cytokinetics Inc., adjusted total assets

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Total assets	1,014,775)	841,319)	533,803)	289,814)	211,178)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	10,355)
Less: Noncurrent deferred tax assets, net²	—)	—)	—)	—)	—)
After Adjustment
Adjusted total assets	1,014,775)	841,319)	533,803)	289,814)	221,533)

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Noncurrent deferred tax assets, net. See details »

Download chart

Cytokinetics Inc., adjusted total liabilities

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Total liabilities	1,122,675)	597,456)	420,420)	300,751)	185,244)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	10,355)
Less: Noncurrent deferred tax liabilities²	—)	—)	—)	—)	—)
Less: Deferred revenue	—)	87,000)	87,000)	—)	—)
After Adjustment
Adjusted total liabilities	1,122,675)	510,456)	333,420)	300,751)	195,599)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Noncurrent deferred tax liabilities. See details »

Download chart

Cytokinetics Inc., adjusted stockholders’ equity (deficit)

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Stockholders’ equity (deficit)	(107,900)	243,863)	113,383)	(10,937)	25,934)
Adjustments
Less: Net deferred tax assets (liabilities)¹	—)	—)	—)	—)	—)
Add: Deferred revenue	—)	87,000)	87,000)	—)	—)
After Adjustment
Adjusted stockholders’ equity (deficit)	(107,900)	330,863)	200,383)	(10,937)	25,934)

¹ Net deferred tax assets (liabilities). See details »

Download chart

Cytokinetics Inc., adjusted capitalization table

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Current portion of term loan	—)	—)	—)	—)	2,607)
Short-term finance lease liabilities	1,000)	500)	—)	—)	—)
Term loan, net, excluding current portion	63,810)	47,367)	46,209)	45,052)	39,806)
Convertible notes, net	545,808)	95,471)	89,504)	84,205)	—)
Long-term finance lease liabilities	1,001)	805)	—)	—)	—)
Total reported debt	611,619)	144,143)	135,713)	129,257)	42,413)
Stockholders’ equity (deficit)	(107,900)	243,863)	113,383)	(10,937)	25,934)
Total reported capital	503,719)	388,006)	249,096)	118,320)	68,347)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	10,355)
Add: Short-term operating lease liabilities²	12,829)	14,863)	2,785)	4,616)	—)
Add: Long-term operating lease liabilities³	126,895)	112,229)	440)	2,195)	—)
Adjusted total debt	751,343)	271,235)	138,938)	136,068)	52,768)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	—)	—)	—)	—)	—)
Add: Deferred revenue	—)	87,000)	87,000)	—)	—)
Adjusted stockholders’ equity (deficit)	(107,900)	330,863)	200,383)	(10,937)	25,934)
After Adjustment
Adjusted total capital	643,443)	602,098)	339,321)	125,131)	78,702)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Short-term operating lease liabilities. See details »

³ Long-term operating lease liabilities. See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Cytokinetics Inc., adjusted revenues

US$ in thousands

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Revenues	94,588)	70,428)	55,828)	26,868)	31,501)
Adjustment
Add: Increase (decrease) in deferred revenue	(87,000)	—)	87,000)	—)	—)
After Adjustment
Adjusted revenues	7,588)	70,428)	142,828)	26,868)	31,501)

Download chart

Cytokinetics Inc., adjusted net loss

US$ in thousands

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Net loss	(388,955)	(215,314)	(127,290)	(121,692)	(106,289)
Adjustments
Add: Deferred income tax expense (benefit)¹	—)	—)	—)	—)	—)
Add: Increase (decrease) in deferred revenue	(87,000)	—)	87,000)	—)	—)
Add: Other comprehensive income (loss)	(2,721)	(1,018)	(530)	179)	157)
After Adjustment
Adjusted net loss	(478,676)	(216,332)	(40,820)	(121,513)	(106,132)

¹ Deferred income tax expense (benefit). See details »

Download chart

Cytokinetics Inc. (NASDAQ:CYTK)

Adjustments to Financial Statements